cystic-fibrosis
(2)
Joel Schneider
Joel Schneider is the founder, president and CEO of Carbon Biosciences, a Waltham, Massachusetts biotech building gene therapies from parvovirus-derived vectors rather than the more common adeno-associated viruses. He launched the company out of stealth in 2022 with a $38 million Series A led by Agent Capital, pairing his operating background with the science of gene therapy pioneer Robert Kotin. Trained as a stem cell biologist with a Rutgers Ph.D. and a Harvard postdoc, Schneider was the first employee at Solid Biosciences before founding Carbon to push vectors that carry larger genetic payloads, target specific tissues such as the lung, and sidestep the pre-existing immunity that limits current gene therapies. Carbon's lead program targets cystic fibrosis.
David Lockhart
David J. Lockhart, Ph.D. is President and Chief Scientific Officer of ReCode Therapeutics, a clinical-stage biotech pioneering nonviral lipid nanoparticle (LNP) delivery of mRNA and gene-editing payloads to the lungs for genetic respiratory diseases including cystic fibrosis and primary ciliary dyskinesia. With more than 25 years in drug discovery and genomics — from co-founding Ambit Biosciences to leading science at Amicus Therapeutics — Lockhart brings rare-disease chops and deep genomics expertise to ReCode's SORT LNP platform, which has raised $345M and dosed its first patients in a Phase 1 PCD trial.